Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Qiagen N.V. Common Shares (NY:QGEN)

39.28 +0.21 (+0.55%)
Streaming Delayed Price Updated: 3:38 PM EDT, Mar 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 Next >
News headline image
Qiagen Announces Form 20-F Annual Report Filing for 2025 Results
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System
From QIAGEN N.V.
Via Business Wire
News headline image
Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Appoints Mark Stevenson to Supervisory Board
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Launches New Automated Sexual Assault Sample Processing Kit at ISHI 2025
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board
From QIAGEN N.V..
Via Business Wire
News headline image
QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN announces plans for transition in leadership of Supervisory Board
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting
From QIAGEN N.V.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.